Advanced search
Publication Cover
Pharmacogenomics Volume 13, 2012 - Issue 14
Submit an article Journal homepage
114
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Association of ERCC1 SNPs with Outcome in Platinum-Treated Patients with Advanced Urothelial Cancer: A Hellenic Cooperative Oncology Group Study

Nikitas Nikitasa Department of Clinical Therapeutics, University of Athens Medical School, Oncology Unit, Alexandra Hospital, 80 Vas. Sofias Avenue, 115 28Athens, Greece
,
Alexandra Karadimoua Department of Clinical Therapeutics, University of Athens Medical School, Oncology Unit, Alexandra Hospital, 80 Vas. Sofias Avenue, 115 28Athens, Greece
,
Eliza Tsitourab Molecular Virology Laboratory, Hellenic Pasteur Institute, Athens, Greece
,
Nikolaos Souposa Department of Clinical Therapeutics, University of Athens Medical School, Oncology Unit, Alexandra Hospital, 80 Vas. Sofias Avenue, 115 28Athens, Greece
,
Marinos Tsiatasa Department of Clinical Therapeutics, University of Athens Medical School, Oncology Unit, Alexandra Hospital, 80 Vas. Sofias Avenue, 115 28Athens, Greece
,
Vasilios Karavasilisc Department of Medical Oncology, Aristotle University of Thessaloniki Medical School, Papageorgiou Hospital, Thessaloniki, Greece
,
Dimitrios Pectasidesd Department of Medical Oncology, Attikon University Hospital, Athens, Greece
,
Nikolaos Pavlidise Department of Medical Oncology, University of Ioannina Medical School, Ioannina, Greece
,
Michael Chrisofosf Department of Urology, Attikon University Hospital, Athens, Greece
,
Ioannis Adamakisg Department of Urology, University of Athens Medical School, Laikon Hospital, Athens, Greece
,
Samuel Murrayh BioMarker Solutions, Department of Oncology, London, UK
,
Georgios Fountzilasi Department of Medical Oncology, Aristotle University of Thessaloniki Medical School
,
Meleios-Athanasios Dimopoulosa Department of Clinical Therapeutics, University of Athens Medical School, Oncology Unit, Alexandra Hospital, 80 Vas. Sofias Avenue, 115 28Athens, Greece
&
Aristotle Bamiasa Department of Clinical Therapeutics, University of Athens Medical School, Oncology Unit, Alexandra Hospital, 80 Vas. Sofias Avenue, 115 28Athens, GreeceCorrespondence[email protected]
 show all
Pages 1595-1607 | Published online: 13 Nov 2012

References

  • Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J. Clin.61 , 69–90 (2011).
  • Siegel R , WardE, BrawleyO et al. Cancer statistics, 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61 , 212–236 (2011).
  • Sternberg C , YakodaA, ScherHI et al. M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol. 139 , 461–469 (1988).
  • Roth BJ , BajorinDF. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J. Urol.153 , 894–900 (1995).
  • Sternberg CN . The treatment of advanced bladder cancer. Ann. Oncol.6 , 113–126 (1995).
  • Von der Maase H , HansenSW, RobertsJT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18 , 3068–3077 (2000).
  • Karadimou A , LianosE, PectasidesD. Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis. Open Access Urol.2 , 1–7 (2010).
  • Reardon JT , SancarA. Nucleotide excision repair. Prog. Nucleic Acid Res. Mol. Biol.79 , 183–235 (2005).
  • Hanawalt PC . Subpathways of nucleotide excision repair and their regulation. Oncogene21 , 8949–8956 (2002).
  • Rabik CA , DolanME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev.33 , 9–23 (2007).
  • Altaha R , LiangX, YuJJ, ReedE. ERCC-1 gene expression and platinum resistance. Int. J. Mol. Med.14 , 959–970 (2004).
  • Arriagada R , BergmanB, DunantA, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med.350 , 351–360 (2004).
  • Olaussen KA , DunantA, FouretP et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355 , 983–991 (2006).
  • Kim KH , DoIG, KimHS et al. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS 118 , 941–948 (2010).
  • Hoffmann AC , WildP, LeichtC et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia12 , 628–636 (2010).
  • Bellmunt J , Paz-AresL, CuelloM et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol. 18 , 522–528 (2007).
  • Yu JJ , LeeKB, MuC et al. Comparison of two human ovarian cancer cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 16 , 555–560 (2000).
  • Chen P , WienckeJ, AldapeK et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers Prev. 9 , 843–847 (2000).
  • Zhou W , GurubhagavatulaS, LiuG et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10 , 4939–4943 (2004).
  • Takenaka T , YanoT, KiyoharaC et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67 , 101–107 (2010).
  • Krivak TC , DarcyKM, TianC et al. Single nucleotide polymorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecol. Oncol. 122 , 121–126 (2011).
  • Moreno V , GemignaniF, LandiS et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin. Cancer Res. 12 , 2101–2108 (2006).
  • Park DJ , ZhangW, StoelmacherJ et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin. Adv. Hematol. Oncol.1 , 162–166 (2003).
  • Sturgis EM , DahlstromKR, SpitzMR, WeiQ. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg.128 , 1084–1088 (2002).
  • Bajorin DF , DoddPM, MazudmarM et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of treatment. J. Clin. Oncol. 17 , 3173–3181 (1999).
  • Bamias A , KaradimouA, LampakiS et al. Prospective, randomized Phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin (MVAC) versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer (ACTRN12610000845033). J. Clin. Oncol. 29 , 291 (2011).
  • Bamias A , LainakisG, KastritisE et al. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy. Report of efficacy, quality of life and geriatric assessment. Oncology 73 , 290–297 (2007).
  • Isal D , SarriesC, RosellR et al. Single nucleotide polymorphisms and outcome in docetaxel-cispaltin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15 , 1194–1203 (2004).
  • Kamikozuru H , KuramochiH, HayashiK et al. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int. J. Oncol.32 , 1091–1096 (2008).
  • Viguier J , BoigeV, MiquelC et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res.11 , 6212–6217 (2005).
  • Kang S , JuW, KimJW et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp. Mol. Med. 38 , 320–324 (2006).
  • Ryu JS , HongYC, HanHS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44 , 311–316 (2004).
  • Stoehlmacher J , ParkDJ, ZhangW et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91 , 344–354 (2004).
  • Krivak TC , DarcyKM, TianC et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group Phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J. Clin. Oncol. 26 , 3598–3606 (2008).
  • Kim HS , KimMK, ChungHH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol. Oncol. 113 , 264–269 (2009).
  • Marsh S , PaulJ, KingCR, GiffordG, McLeodHL, BrownR. Pharmacogenetic assessment of toxicity and outcome after platinum taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J. Clin. Oncol.25 , 4528–4535 (2007).
  • Jordheim LP , SèveP, TrédanO et al. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 12 , 693–702 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.